#covid testing centre uk

[conceptodiagnostics]

3 Benefits of Corporate Covid-19 Testing

Coronavirus is a respiratory disease brought about by SARS-CoV-2. Most patients contaminated with Covid report gentle to direct side effects and recuperate with the Private Pathology Laboratory in the UK. Nonetheless, patients with previous medical conditions like hypertension, disease, and diabetes might encounter unfavorable impacts. In any case, note that anybody can get the infection, become sick or even kick the bucket, no matter what their age.

 When can you use Corporate Covid-19 testing?

You ought to get tired or Book a Covid-19 Travel Test from the Clinic of the UK, assuming you experience any side effects of Coronavirus, regardless of whether you have gotten every one of the essential antibodies.

Note that Covid spreads rapidly and effectively, even before seeing any side effects. Thusly, the sooner you know whether you have the infection, the better since you can detach it and lessen the possibility of spreading it to other people.

Once in a while you might test negative for the infection yet feel unwell, demonstrating a bogus negative. In such a situation, you ought to disengage and contact your primary care physician to examine your side effects. Nonetheless, assuming you test positive, you should promptly detach and contact your Private Blood Tests Clinic in the UK to begin the treatment plan.

According to Diagnostic Centre in UK, you ought to do a test following five to seven days on the off chance that you are immunized against the infection. Furthermore, if you're not immunized, you ought to get a test. Given below are the 3 Benefits of Corporate Covid-19 testing:

1.    Ensures Successful Detachment

There are various difficulties confronting the battle against the spread of Covid. Luckily, medical services suppliers can utilize fast testing from the Corporate Coronavirus Testing of the UK to analyze whatever number of Coronavirus cases would be prudent before the infection spreads to the more extensive populace.

2.    Simple to Utilize

You don't need to be a clinical expert to do a quick Coronavirus test. You can do it with your family utilizing a home Coronavirus test pack.

3.    Mitigates Financial Effect

With fast testing, people presented with the infection accept their test results within a couple of hours, implying that they don't need to disengage for a long time or miss various business days as they hold back to accept their experimental outcomes. For more information visit the Private Pathology Laboratory in the UK.

 It can be concluded that Patients go through analytic tests from the Diagnostic Centre in the UK to affirm the presence of Coronavirus respiratory sickness. At the point when patients test positive for a fast antigen test, they are disengaged and begin treatment right away.

 Also Read: What Is So Fascinating About the Covid-19 Antigen LFT Test?

[covid-safer-hotties]

Reference archived on our website

Published in the Summer of 2021. Those "experts" who are shocked to find out that covid has lingering effects aren't as expert or informed as they like to act.

Abstract Background There is growing concern about possible cognitive consequences of COVID-19, with reports of ‘Long COVID’ symptoms persisting into the chronic phase and case studies revealing neurological problems in severely affected patients. However, there is little information regarding the nature and broader prevalence of cognitive problems post-infection or across the full spread of disease severity.

Methods We sought to confirm whether there was an association between cross-sectional cognitive performance data from 81,337 participants who between January and December 2020 undertook a clinically validated web-optimized assessment as part of the Great British Intelligence Test, and questionnaire items capturing self-report of suspected and confirmed COVID-19 infection and respiratory symptoms.

Findings People who had recovered from COVID-19, including those no longer reporting symptoms, exhibited significant cognitive deficits versus controls when controlling for age, gender, education level, income, racial-ethnic group, pre-existing medical disorders, tiredness, depression and anxiety. The deficits were of substantial effect size for people who had been hospitalised (N = 192), but also for non-hospitalised cases who had biological confirmation of COVID-19 infection (N = 326). Analysing markers of premorbid intelligence did not support these differences being present prior to infection. Finer grained analysis of performance across sub-tests supported the hypothesis that COVID-19 has a multi-domain impact on human cognition.

Interpretation Interpretation. These results accord with reports of ‘Long Covid’ cognitive symptoms that persist into the early-chronic phase. They should act as a clarion call for further research with longitudinal and neuroimaging cohorts to plot recovery trajectories and identify the biological basis of cognitive deficits in SARS-COV-2 survivors.

Funding Funding. AH is supported by the UK Dementia Research Institute Care Research and Technology Centre and Biomedical Research Centre at Imperial College London. WT is supported by the EPSRC Centre for Doctoral Training in Neurotechnology. SRC is funded by a Wellcome Trust Clinical Fellowship 110,049/Z/15/Z. JMB is supported by Medical Research Council (MR/N013700/1). MAM, SCRW and PJH are, in part, supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London

[mariacallous]

Protesters across China have made one thing very clear: after three years of harsh restrictions, many people are tired of their government’s pursuit of an increasingly ineffective zero-Covid strategy. China once celebrated its success in containing outbreaks and keeping its economy running, but it has been slow to adapt to a world of more infective variants and mass vaccination. As life begins to feel increasingly normal in Britain and elsewhere, 49 cities – representing a third of China’s population and two-fifths of its economic output – are in partial or total lockdown.

The protests will put pressure on the regime to change its approach, but that may be easier said than done. China has been highly politically committed to its Covid policy, even as it has become less and less tenable. And the situation with its health system, population immunity and vaccine stocks is vastly different from ours, partly because of the choices it made earlier in the pandemic. China will have to face some form of living with Covid soon, and millions of lives – not to mention global economic stability – depend on how this happens.

China was an early adopter of overwhelming measures to contain Covid. This involved recurrent lockdowns affecting millions, but also building isolation centres and hospitals very quickly, mass PCR testing, intensive contact tracing and surveillance, and mandatory masking. Some of the measures were incredibly draconian. Yet, despite the cost to civil liberties, it worked in stopping Covid-19 initially.

But then in 2021, several safe and effective vaccines were approved, which meant that widespread protection could be delivered to western populations. Take-up was remarkably high, and country after country, including maximum suppression countries such as New Zealand, Australia and South Korea, pivoted from containment to mass vaccination, access to antiviral therapies and “living with Covid-19”.

China, though, stayed with its strategy of elimination within its borders. The Chinese government did roll out its homegrown vaccine but took a different approach than the west. Its vaccination priority list focused on healthy young adults, and instead noted the side-effects of the vaccine to elderly groups. It didn’t promote the vaccine to elderly groups until November 2021, but by this time considerable vaccine scepticism had built up. Rising concerns about the low effectiveness of the non-mRNA Chinese vaccines were also a concern: studies indicated that protection faded fast and was undetectable after six months.

Recent reports suggest that only about 40% of over-80s have received a booster shot, and millions still remain unvaccinated. To put this in perspective, the overall booster rate was more than 90% in Japan while only 68% in China. And the Chinese government’s efforts to push vaccination have been met by a population used to zero-Covid messaging and having a false sense of security that they won’t ever be exposed to the virus, so why get vaccinated at all?

And population exposure has been minimal in China. It has had just under 1.5m infections in a population of 1.4 billion, and the national death toll is 5229. Compare this with England where the Financial Times estimates that more than 90% of the population has had Covid at least once. This hybrid “wall of immunity” in Britain has come at a major cost: the UK death rate stands at 2,400 per million, compared with just three deaths in a million in China.

All of this means that China’s population has a lower vaccination rate, with vaccines that appear less effective, than in most other countries. And many people don’t have any immunity gained from a previous infection either. If China gives up on containment and allows a large wave of infections, the country will take a huge loss of life given current vaccination levels: they are just too low in the most at-risk groups. This would overwhelm the already fragile Chinese healthcare system with too many patients who need care.

And the 2020 playbook isn’t working in 2022 in China, with a much more infectious version of the virus – Omicron – and a population fed up and tired of restrictions and constantly changing rules. Millions of businesses have had to shut down and the country has taken a major economic hit: the World Bank forecasts GDP growth in China of just 2.8%, behind the rest of the region’s average of 5.3%. This is the first time China’s GDP growth is less than its neighbours since 1990. Yet there are few signs the government will change tack for political and health system reasons.

Politically, the president, Xi Jinping, has projected a clear narrative of protecting China’s population through a zero-Covid policy and sees it as one of his successes. He defended the strategy vigorously at the recent Communist party congress, and any sudden policy shift may be seen as an admission of failure. And while there are increasing protests against restrictions, other parts of the country are calling for authorities to do everything to protect them from Covid. They’ve heard about the death toll in the western world and don’t want to be exposed to the virus.

The other concern of Chinese scientists and politicians is long Covid, which some feel has been underestimated in western countries. And you can understand this concern. An estimated 2 million people are suffering from long Covid in Britain and it is cited as one of the major reasons for the rising number of “economically inactive” people.

No matter what approach China takes, it needs to improve its vaccines. But to do this it will need access to mRNA technology, and this has been stuck at an impasse. Moderna has refused to transfer its technology to Chinese firms for manufacturing, instead eager to sell directly to a large market. China has instead worked to develop a homegrown mRNA vaccine but this has caused delays in rollout.

The countries that dealt most successfully with the pandemic, such as New Zealand, South Korea, Japan, Denmark and others, did it by successfully moving from containment in 2020 to mass vaccination and treatments in 2021 and 2022. This is the only sustainable exit from this pandemic and we’re likely to see China take this route eventually. It will need to get mRNA vaccines to the biggest priority groups quickly, and also bring an exhausted public along through what is likely to be a jarring shift in strategy – from no Covid at all, to Covid circulation with vaccine protection.

Let’s hope China makes this transition before it is forced, regardless of what the governments wants, to live with Covid before it is ready. China buckling under a wave of Covid would affect the entire world, not just disrupting economic stability but potentially creating new variants that could set progress back everywhere.

[min-phone-pyae]

COVID FLiRT variants KP.3 and XEC: What you need to know

KP.3 was the 'predominant' SARS-CoV-2 variant in the US. It was also spreading in Europe. It's now joined with another variant and become XEC.

Over the European summer, the number of COVID-19 infections rose again, with test positivity for SARS-CoV-2 above 20%. Globally, test positivity was about 10%.

The US also saw a rise in hospitalizations, apparently after a wave of COVID-19 infections in Singapore.

Now, as we in the northern hemisphere move into autumn and winter, there is concern about two new variants.

The first one is known as KP.3 and its sub-variant KP.3.1.1. The second is XEC, a "recombinant" variant which is related to KP.3.

KP.3 is considered a global Variant of Concern (VOC) in the US by The US Center for Disease Control and Prevention (CDC) because KP.3 was "predominant" there in August. VOCs may spread more easily or cause more severe illness.

It's important to note that KP.3 is not a global VOC, only in the US.

The CDC recommended people get an updated 2024–2025 COVID-19 vaccine.

What are the KP.3 and XEC variants?

KP.3 is one of a group of SARS-CoV-2 variants known as FLiRT variants. SARS-CoV-2 is the base virus that causes COVID, the illness.

As the name KP.3 suggests, there are also KP.1 and KP.2 sub-variants. KP.3 became predominant because it is more infectious than other circulating sub-variants.

KP.3 and other FLiRT variants descend from the omicron variant of SARS-CoV-2.

Now, think of a family tree: The KP variants are children of the JN.1 variant. And JN.1 is, in turn, a child of omicron variant BA.2.86.

How omicron evolved into the subvariants KP.3. and XEC

This is important to know because of all the major COVID variants, omicron remains dominant, globally. You'll recall, other major variants are alpha, beta, delta, and gamma.

But omicron keeps evolving or mutating into new variants and sub-variants.

XEC the sub-variant is believed to have formed when KP.3 joined with KS.1.1. But we don't know for sure.

As Francois Balloux, Professor of Computational Systems Biology and Director at the UCL Genetics Institute, UK, told the Science Media Centre, "XEC is a likely recombinant between the subvariants KP.3.3 and KS.1.1."

XEC COVID variant in Germany

XEC has been reported as being first detected in Germany in June. But it is yet to appear on the Robert Koch Institute's COVID Dashboard.

As a spokesperson from the Robert Koch Institute implied via email, XEC may never appear on the dashboard because it is "impossible to predict how individual variants will spread."

Since June, the number of XEC cases in Germany has been in double-digits, but the spokesperson did not specify further. The RKI's doesn't even mention XEC on its weekly assessment, published September 18, 2024.

The focus in Germany remains on KP.3.1.1, which is dominant and considered more infectious than previous variants.

In an interview with the DPA news agency, virologist Sandra Ciesek said it was no surprise that KP.3.1.1 was more infectious.

"The virus keeps mutating in search of new ways to infect people […] but that doesn't mean that the variant causes a more severe illness," said Ciesek, who's based at the German Center for Infection Research.

How prevalent are KP.3.1.1, KS.1.1 and XEC? Up to September 3, KP.3.1.1 remains the most dominent variant, according to data provided by GISAID, the Global Initiative on Sharing All Influenza Data, and presented by outbreak.info.

KP.3.1.1 was detected worldwide 14,396 times

KP.3.3 was detected worldwide 9,157 times

KS.1.1 was detected worldwide 2,650 times

XEC was detected worldwide 95 times

[prolife-home-care]

XEC Covid Variant: Symptoms, Spread, and How to Stay Protected This Winter

A new coronavirus variant, XEC, is rapidly spreading and could soon become the dominant strain this winter, according to scientists. First identified in Germany in June, XEC has since been reported in the UK, the US, Denmark, and other countries. Experts are now monitoring its growth closely, anticipating its potential impact during the colder months.

What Is the XEC Covid Variant?

XEC is a recombinant variant that combines characteristics of two previous Omicron subvariants: KS.1.1 and KP.3.3. These parent strains have contributed to recent Covid waves across the globe. KS.1.1, known as one of the "FLiRT variants," and KP.3.3, a part of the "FLuQE" family, exhibit unique mutations in the spike protein, giving XEC an edge in transmission.

Dr. Peter Chin-Hong, an infectious disease specialist at UCSF, notes that XEC possesses "tighter binding cells," potentially making it more transmissible and possibly more immune-evasive than earlier variants. While XEC may not cause a significant spike in hospitalizations or deaths, its enhanced ability to spread has scientists on alert.

How Does XEC Differ from Previous Variants?

XEC has unusual mutations, such as the T22N mutation and additional changes in the spike protein. These differences could provide it with a slight transmission advantage over other Covid variants circulating this fall. However, because XEC belongs to the Omicron lineage, its symptoms and overall severity are expected to be similar to those of previous Omicron strains.

Current Statistics on XEC and Covid-19 Spread

While specific case numbers for the XEC variant are limited, global health authorities continue to monitor its spread along with other Covid-19 variants. The World Health Organization (WHO) reports that globally, during the four-week period from June 24 to July 21, 2024, new Covid-19 cases increased by 30% and deaths by 26% compared to the previous 28-day period, with over 186,000 new cases reported across 96 countries​(World Health Organization (WHO). This surge indicates that new variants like XEC may be contributing to the recent increase in cases.

The Centers for Disease Control and Prevention (CDC) in the United States provides regular updates on Covid-19 trends, including hospitalizations, emergency department visits, and test positivity rates. However, specific data on the XEC variant's prevalence in the U.S. is not yet available​(CDC COVID-19 Data Tracker). Monitoring the overall Covid-19 trends is crucial as new variants emerge, especially as the XEC variant is believed to have a transmission advantage.

The European Centre for Disease Prevention and Control (ECDC) actively tracks and classifies SARS-CoV-2 variants of concern and interest. Detailed data on the spread of various variants, including XEC, across the EU/EEA, is regularly published, although specific numbers on XEC’s prevalence are still being analyzed​.

Symptoms of XEC Covid

The symptoms of the XEC variant are similar to those of previous Omicron variants. These include:

High temperature or fever

Cough and sore throat

Fatigue and body aches

Loss of smell and appetite

Congestion and runny nose

Nausea, vomiting, or diarrhea in some cases

Most people recover within a few weeks, but those who are at higher risk, such as older adults or immunocompromised individuals, may experience more severe illness.

How Is XEC Spreading?

XEC has shown strong growth in Europe, especially in Denmark and Germany. Eric Topol, director of the Scripps Research Translational Institute, has suggested that XEC could become the next dominant variant over the winter. However, this process may take several weeks or even a couple of months.

Monitoring the spread of XEC is more challenging now due to less routine Covid testing compared to previous years. Health agencies, such as the CDC, are using alternative methods like wastewater surveillance to keep track of the virus's spread. Despite these limitations, early indications show that XEC is on the rise in various countries.

How Effective Are Current Vaccines Against XEC?

Since XEC is an offshoot of the Omicron lineage, existing vaccines are expected to provide protection against severe illness caused by this variant. Dr. Chin-Hong has expressed confidence in the updated vaccines, especially for those at higher risk, including older adults and individuals with weakened immune systems.

The vaccines, updated to target recent Covid variants, may not be specifically designed for XEC but should still offer a buffer of protection. Health experts recommend getting the updated booster shots to reduce the chance of infection and lower the risk of developing long Covid.

Who Should Get the Booster Shot?

Health authorities recommend that the following groups receive the updated booster:

Adults aged 65 years and over

Residents of care homes

Individuals over six months old in clinical risk groups

Front-line healthcare and social-care workers

The main vaccination drive for both flu and Covid-19 is set to start in October. However, those at higher risk or planning to travel in the fall should consider getting their booster shot earlier.

Expert opinion

Getting vaccinated is super important, especially for older adults. As we age, our immune systems just don’t work as well, which makes seniors more vulnerable to serious illnesses like COVID-19. During the pandemic, older adults were hit the hardest. In fact, according to the CDC, over 80% of COVID-19 deaths in the U.S. were among those 65 and older. This really shows why getting vaccinated is a must – it significantly reduces the risk of severe illness and death in older adults. Plus, it helps take some of the strain off our healthcare system and keeps our communities healthier overall.

Best regards, Anna Klyauzova LinkedIn Profile Prolife Home Care

Protect Yourself This Winter

As the XEC variant continues to spread, it's important to follow public health guidelines to stay protected. In addition to getting vaccinated, wearing masks in crowded places, practicing good hand hygiene, and maintaining social distancing can help reduce the risk of infection.

FAQs About the XEC Covid Variant

Q: What are the symptoms of the XEC variant? A: The symptoms are similar to previous Omicron variants and include fever, cough, sore throat, fatigue, body aches, congestion, and gastrointestinal issues.

Q: How is XEC different from other Covid variants? A: XEC is a recombinant variant from two Omicron subvariants, KS.1.1 and KP.3.3, with unique mutations that could make it more transmissible.

Q: Are current vaccines effective against the XEC variant? A: Yes, existing vaccines are expected to provide protection against severe illness caused by XEC, though they may not completely prevent infection.

Q: Who should get the updated Covid booster? A: Adults over 65, care home residents, people in clinical risk groups, and front-line healthcare workers are recommended to get the booster.

Conclusion

The XEC variant serves as a reminder that the Covid-19 virus continues to evolve. While vaccines may not be a complete shield against infection, they remain the best defense against severe illness and hospitalization. Global trends indicate a rise in Covid-19 cases, highlighting the importance of staying informed and following health recommendations. By getting vaccinated and adhering to public health guidelines, you can protect yourself and those around you as the winter season approaches.

[harleystreetent-uk]

Top ENT Clinic in London: Expert Care for Your Health

 London is home to some of the most advanced healthcare facilities, and when it comes to ear, nose, and throat ent clinic londone, Harley Street ENT Clinic stands out as one of the foremost private medical centres in the UK. If you are experiencing issues related to your ears or looking for a specialist to diagnose and treat your condition, choosing the right ear specialist in London is crucial for quick relief and long-term health.

In this guide, we will explore the world of ENT care and how Harley Street ENT Clinic can provide the best treatment solutions for you

Why You Need an Ear Specialist in London

An ear specialist or an otologist is a doctor who focuses on diagnosing and treating disorders related to the ears, such as:

Hearing loss

Tinnitus

Ear infections

Balance issues

Vertigo

Ear pain

If you have been suffering from any of these symptoms, seeing a qualified ear specialist can help you find the right treatment and improve your quality of life.

Harley Street ENT Clinic: Leading Ear Specialists in London

At Harley Street ENT Clinic, our team of experienced ENT specialists offers comprehensive care for all ear, nose, and throat conditions. As a private medical centre, we prioritize patient comfort and ensure you receive world-class treatment in a safe, COVID-secure environment.

What Sets Us Apart:

COVID-Safe Facilities: We follow strict health protocols, including HEPA viral filtration units in all examination rooms, to protect our patients.

Advanced Diagnostic Tools: Our clinic is equipped with state-of-the-art technology to offer precise diagnoses.

Same-Day Appointments: No need to wait – you can access expert care promptly, with appointments available on the same day.

Tailored Treatment Plans: Whether you need medical treatment, hearing aids, or surgery, we design treatment plans specifically for your condition.

Expert ENT Specialists: Our ENT specialists are renowned for their expertise, ensuring that you are in the best hands for your ear, nose, and throat care.

Common Ear Conditions Treated at Harley Street ENT Clinic

If you are searching for an ENT clinic in London, Harley Street offers a wide range of treatments for common ear conditions:

1. Tinnitus

Tinnitus, or ringing in the ears, can be extremely disruptive. Our specialists use advanced diagnostics to uncover the cause and recommend treatments that could include sound therapy, hearing aids, or medications.

2. Hearing Loss

Hearing loss affects millions of people, and we offer comprehensive audiology services, including hearing tests and the latest in hearing aid technology.

3. Ear Infections

From childhood ear infections to chronic middle ear infections, our clinic treats infections effectively with antibiotics, ear cleaning, and surgery if necessary.

4. Balance Disorders

If you’re experiencing dizziness, vertigo, or balance issues, our team will assess your condition and suggest vestibular rehabilitation or other treatments to restore balance.

Why Harley Street ENT Clinic Is Your Top Choice for ENT Care

Choosing the right ENT clinic in London is important for receiving the best care and achieving long-term results. Harley Street ENT Clinic offers:

Patient-Centered Care: We believe in putting our patients first, ensuring that your experience at our clinic is comfortable and stress-free.

Top ENT Specialists: Our consultants have years of experience and are recognized for their expertise in treating complex ear conditions.

Comprehensive Services: From diagnosis to treatment, you can receive all necessary care under one roof, saving you time and hassle.

Book an Appointment with an Ear Specialist in London Today

At Harley Street ENT Clinic, we understand that ear problems can significantly impact your quality of life. With our team of expert ear specialists in London, you can rest assured that you’ll receive the highest standard of care. Whether you need a routine check-up or specialized treatment, our clinic is ready to assist you.

For same-day appointments and expert ENT care, contact us today at 020 7224 2350 or visit our clinic on Harley Street. Visit Us Nowent.com:  https://www.harleystreet/

[head-post]

New lung cancer-fighting jab tested in UK for first time

Doctors have begun trials of the world’s first mRNA lung cancer vaccine on patients, with experts hailing its “revolutionary” potential to save thousands of lives.

Lung cancer is the leading cause of cancer deaths worldwide, with around 1.8 million people dying from it each year. Survival rates are particularly poor in patients with late-stage forms of the disease, when tumours spread.

Now experts are testing a new shot that causes the body to track down and destroy cancer cells and then prevent them from returning. The vaccine, known as BNT116 and created by BioNTech, is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

The Phase 1 clinical trial, the first human study of BNT116, has begun at 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

The UK has six centres located in England and Wales, and the first UK patient received his initial dose on Tuesday.

In total, around 130 patients – ranging from those with early-stage disease before surgery or radiotherapy, to those with late-stage disease or recurrent cancer – will be registered for the vaccination alongside immunotherapy. There will be around 20 people from the UK.

The vaccination uses information RNA (mRNA), similar to the COVID-19 vaccines, and works by giving the immune system tumour markers from NSCLC to prepare the body to fight cancer cells expressing these markers.

Lung cancer vaccine development underway since March

Researchers from Oxford University, the Francis Crick Institute and University College London (UCL) selected the technology used to create the Oxford-AstraZeneca vaccine against COVID-19 in March. The new drug trains the immune system to recognise neoantigens in lung cancer cells and destroy them.

The team has received funding of up to £1.7m from charities Cancer Research UK and CRIS Cancer Foundation to produce 3,000 doses of the vaccine. The aim is to boost a person’s immune response to cancer while leaving healthy cells intact, unlike chemotherapy. Prof. Siow Ming Lee, a consultant medical oncologist at University College London hospitals NHS foundation trust (UCLH), which is leading the trial in the UK, said:

“We are now entering this very exciting new era of mRNA-based immunotherapy clinical trials to investigate the treatment of lung cancer. It’s simple to deliver, and you can select specific antigens in the cancer cell, and then you target them. This technology is the next big phase of cancer treatment.”

Read more HERE

[tamanna31]

Biobanks Market 2024 Analysis, Research, Review, Applications and Forecast to 2030

Biobanks Industry Overview

The global biobank market size was estimated at USD 76.74 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2030.

High investments in the R&D of advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, are some of the driving factors. Moreover, the onset of COVID-19 has put biobanks at the forefront of the pandemic control measures, resulting in the organic revenue growth of the market. The COVID-19 outbreak had a major influence on the biobanking industry. Biobanking is important for the diagnosis & production of medicines for a variety of disorders. International initiatives to produce vaccines and other medicines to prevent the spread of the virus have been urgently needed.

The collection, processing, and analysis of patient samples are at the frontline of the COVID-19 crisis. For example, the Health Minister announced EUR 2 million in financing for the National Irish COVID-19 Biobank (NICB) in a July 2021 update from the Government of Ireland. The NICB has become a critical part of Ireland’s COVID-19 pandemic response. According to a February 2021 release, the Sample Collection Database was designed by the SciLifeLab Data Centre in partnership with Biobank Sweden and the research area ‘Biobanks for COVID-19’ of the SciLifeLab & KAW National COVID-19 research program.

Gather more insights about the market drivers, restrains and growth of the Biobanks Market

Furthermore, Tulane University announced a new COVID-19 biobank containing blood & cell samples from survivors in July 2021 to aid researchers in determining why some people heal rapidly while others have long-term effects. As a result, such activities show that the outbreak of the pandemic boosted the demand for biobank services, benefiting the global economy.

The increasing popularity of precision/personalized medicine and genetic testing has been a key driver of the market. Biobanks have been playing a significant role in biomedical research. Over the past few decades, there have been several advances in platforms and tools used in genetic studies. This has led to an increase in demand for biospecimens from clinical labs to develop assays for genetic testing. Collaborations between private and public institutions in biobanking have played a crucial role in market progression.

Digitalization, precision medicine, and virtualization are rapidly changing the biobanking industry through the development of novel methods and concepts of synergies initiated by public and private organizations. Companies across all fields are partnering with biobanks, which accelerates the market revenue. For instance, in October 2023, UK Biobank partnered with several philanthropists. Through this partnership, UK Biobank will access USD 34.5 million in funding.

An exponential increase in the number of global cases has rendered the significance of biobanks in containing the spread of the virus. High-quality COVID-19 specimens are required and helpful for both research and diagnostic purposes, and biobanks are considered vital repositories for these samples. Thus, biobanks are gaining ground to support clinical research and drug discovery processes to combat this global disaster.

Developing countries from the Middle East region are investing in biobanks to advance the medical research domain in the country. For instance, in September 2023, the Crown Prince of Abu Dhabi announced the launch of a biobank to support the requirement of personalized medicine through advanced treatments that utilize human tissues and stem cells in medical research. This research will help treat over 80 diseases and immune system issues. Moreover, it strengthens the position of the UAE in the global biobanks market.

Browse through Grand View Research's Biotechnology Industry Research Reports.

The global plasmid purification market size was estimated at USD 1.72 billion in 2023 and is projected to grow at a CAGR of 11.60% from 2024 to 2030. 

The global enzymatic DNA synthesis market size was estimated at USD 232.4 million in 2023 and is projected to grow at a CAGR of 26.4% from 2024 to 2030.

Key Companies & Market Share Insights

Some of the key players operating in the market are adopting various organic & inorganic strategies such as collaborations with biobanking service providers and technological innovation to advance their product offerings in the biobanking industry. 

Key Biobanks Companies:

Thermo Fisher Scientific Inc.

Merck KGaA

Qiagen

Hamilton Company

Tecan Trading AG

Danaher Corporation

Becton, Dickinson, and Company (BD)

Biocision, LLC.

Taylor-Wharton

Charles River Laboratories

Lonza

Stemcell Technologies

Biovault Family

Promocell Gmbh

Precision Cellular Storage Ltd. (Virgin Health Bank)

Recent Developments

In October 2023, AstraZeneca research announced unique relationships between rare changes in plasma proteins and genes that could enhance drug discovery with data from more than 50,000 UK Biobank participants.

Similarly, in January 2023, Hamad Medical Corporation, in collaboration with Qatar BioBank, launched a Tissue Biobank Service in Qatar. This biobank will focus on collecting samples and finding new potential treatments for heart diseases & cancer.

In January 2023, Quibim and European Commission launched European Commission’s European Federation for Cancer Images (EUCAIM) biobank. This biobank will focus on developing treatments for cancers along with early detection techniques.

In December 2023, Charles River Laboratories International, Inc. announced an agreement with CELLphenomics to expand 3D In Vitro Services for drug screening of cancer therapy. CELLphenomics biobank has over 500 in vitro models from around 20 tumor entities. It offers one of the largest complex in vitro models of rare and ultra-rare tumors like thymomas or sarcomas.

. In July 2023, Tecan announced the launch of Phase Separator. It has several applications in biobanking and liquid biopsy and is expected to benefit proteomics, genomics and across numerous disease areas, from neurodegenerative and oncology diseases to metabolic disorders.

In January 2023, Thermo Fisher Scientific, Inc. announced its participation as a founding sponsor of Momentum Labs, a new biotech hub located in Alachua, Florida. This collaboration aims to support the growth of innovative biotech startups and drive advancements in the industry. With Thermo Fisher's expertise in the life sciences and its commitment to innovation, the company is well-positioned to play a significant role in the success of Momentum Labs and the companies it supports. The establishment of this hub is expected to have a positive impact on the local economy and further solidify Florida's position as a hub for biotech innovation.

In February 2022, Hamilton company expanded its range of VersoQ series of storage systems at a debut at SLAS 2022 conference. This would increase the company’s product offerings in biobanking.

Order a free sample PDF of the Biobanks Market Study, published by Grand View Research.

[themathomhouse]

In the UK, n95 masks are called FFP3 and you can buy a box here: https://www.medisave.co.uk/products/drager-ffp3-mask

You can also get covid tests there, or if you qualify for the booster vaccines you can still order them for free from the NHS.

If you don't qualify for the booster vaccines or the flu vaccine, here are your options:

1. You can get the flu jab from a pharmacy, it's usually about £10

2. Call your GP and ask! Some GPs might turn you down but others will happily give you another.

3. Check that you had all three doses. If you didn't you qualify to get them all still.

4. Make sure you actually don't qualify. If you have any kind of underlying illness, or you get especially ill with covid, or you work with vulnerable people, or you provide any kind of care - you qualify. When I got my booster this winter, I didn't have to bring any proof I qualified. I just turned up at the vaccine centre and told them I did.

You're not taking resources from anyone, protecting yourself and everyone else is the best thing you can do other than wearing a mask.

i havent seen much talk about this upcoming covid surge on tumblr so im going to. please please please take covid seriously. this post holiday surge is predicted to be larger than the majority of the pandemic

at least mask up as it offers protection for you and others. if you can get the most current vaccine or at least a booster before the surge hits, stay on top of immune boosting supplements like vitamin c+d and zinc and avoid crowded places

i know a lot of us arent in a place where we can just avoid the public all together but wearing gloves if your going to a grocery store or finding low traffic times to shop are better than nothing

[hardynwa]

WHO warns as new JN.1 Covid variant continues global spread

A sub-variant of the Omicron strain of coronavirus has been classified as a "variant of interest" by the World Health Organization, because of "its rapidly increasing spread". JN.1 has been found in many countries around the world, including India, China, UK and the United States. The risk to the public is currently low and current vaccines continue to offer protection, the WHO says. But it warns Covid and other infections could rise this winter. Respiratory viruses such as flu, respiratory syncytial virus (RSV) and childhood pneumonia are also on the rise in the northern hemisphere. The virus which causes Covid is constantly changing over time and sometimes this leads to new variants developing. Omicron has been the globally dominant variant for some time. The World Health Organization (WHO) is currently tracking a number of variants of interest linked to Omicron - including JN.1 - although none of them are deemed to be concerning. But JN.1 is spreading quickly in many corners of the world. It is currently the fastest-growing variant in the United States, according to the US Centres for Disease Control and Prevention, accounting for 15-29% of infections. The UK Health Security Agency says JN.1 currently makes up around 7% of positive Covid tests analysed in a lab. It said it would continue to monitor all available data on this and other variants. Read the full article

[covid-safer-hotties]

Patients With Long-COVID Show Abnormal Lung Perfusion Despite Normal CT Scans - Published Sept 12, 2024

VIENNA — Some patients who had mild COVID-19 infection during the first wave of the pandemic and continued to experience postinfection symptoms for at least 12 months after infection present abnormal perfusion despite showing normal CT scans. Researchers at the European Respiratory Society (ERS) 2024 International Congress called for more research to be done in this space to understand the underlying mechanism of the abnormalities observed and to find possible treatment options for this cohort of patients.

Laura Price, MD, PhD, a consultant respiratory physician at Royal Brompton Hospital and an honorary clinical senior lecturer at Imperial College London, London, told Medscape Medical News that this cohort of patients shows symptoms that seem to correlate with a pulmonary microangiopathy phenotype.

"Our clinics in the UK and around the world are full of people with long-COVID, persisting breathlessness, and fatigue. But it has been hard for people to put the finger on why patients experience these symptoms still," Timothy Hinks, associate professor and Wellcome Trust Career Development fellow at the Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre senior research fellow, and honorary consultant at Oxford Special Airway Service at Oxford University Hospitals, England, who was not involved in the study, told Medscape Medical News.

The Study Researchers at Imperial College London recruited 41 patients who experienced persistent post-COVID-19 infection symptoms, such as breathlessness and fatigue, but normal CT scans after a mild COVID-19 infection that did not require hospitalization. Those with pulmonary emboli or interstitial lung disease were excluded. The cohort was predominantly female (87.8%) and nonsmokers (85%), with a mean age of 44.7 years. They were assessed over 1 year after the initial infection.

Exercise intolerance was the predominant symptom, affecting 95.1% of the group. A significant proportion (46.3%) presented with myopericarditis, while a smaller subset (n = 5) exhibited dysautonomia. Echocardiography did not reveal pulmonary hypertension. Laboratory findings showed elevated angiotensin-converting enzyme and antiphospholipid antibodies. "These patients are young, female, nonsmokers, and previously healthy. This is not what you would expect to see," Price said. Baseline pulmonary function tests showed preserved spirometry with forced expiratory volume in 1 second and forced vital capacity above 100% predicted. However, diffusion capacity was impaired, with a mean diffusing capacity of the lungs for carbon monoxide (DLCO) of 74.7%. The carbon monoxide transfer coefficient (KCO) and alveolar volume were also mildly reduced. Oxygen saturation was within normal limits.

These abnormalities were through advanced imaging techniques like dual-energy CT scans and ventilation-perfusion scans. These tests revealed a non-segmental and "patchy" perfusion abnormality in the upper lungs, suggesting that the problem was vascular, Price explained.

Cardiopulmonary exercise testing revealed further abnormalities in 41% of patients. Peak oxygen uptake was slightly reduced, and a significant proportion of patients showed elevated alveolar-arterial gradient and dead space ventilation during peak exercise, suggesting a ventilation-perfusion mismatch.

Over time, there was a statistically significant improvement in DLCO, from 70.4% to 74.4%, suggesting some degree of recovery in lung function. However, DLCO values did not return to normal. The KCO also improved from 71.9% to 74.4%, though this change did not reach statistical significance. Most patients (n = 26) were treated with apixaban, potentially contributing to the observed improvement in gas transfer parameters, Price said.

The researchers identified a distinct phenotype of patients with persistent post-COVID-19 infection symptoms characterized by abnormal lung perfusion and reduced gas diffusion capacity, even when CT scans appear normal. Price explains that this pulmonary microangiopathy may explain the persistent symptoms. However, questions remain about the underlying mechanisms, potential treatments, and long-term outcomes for this patient population.

Causes and Treatments Remain a Mystery Previous studies have suggested that COVID-19 causes endothelial dysfunction, which could affect the small blood vessels in the lungs. Other viral infections, such as HIV, have also been shown to cause endothelial dysfunction. However, researchers don't fully understand how this process plays out in patients with COVID-19.

"It is possible these patients have had inflammation insults that have damaged the pulmonary vascular endothelium, which predisposes them to either clotting at a microscopic level or ongoing inflammation," said Hinks.

Some patients (10 out of 41) in the cohort studied by the Imperial College London's researchers presented with Raynaud syndrome, which might suggest a physiological link, Hinks explains. "Raynaud's is a condition of vascular control or dysregulation, and potentially, there could be a common factor contributing to both breathlessness and Raynaud's."

He said there is an encouraging signal that these patients improve over time, but their recovery might be more complex and lengthy than for other patients. "This cohort will gradually get better. But it raises questions and gives a point that there is a true physiological deficit in some people with long-COVID."

Price encouraged physicians to look beyond conventional diagnostic tools when visiting a patient whose CT scan looks normal yet experiences fatigue and breathlessness. Not knowing what causes the abnormalities observed in this group of patients makes treatment extremely challenging. "We need more research to understand the treatment implications and long-term impact of these pulmonary vascular abnormalities in patients with long-COVID," Price concluded.

[rowanthehumannottheplant]

04/10/2023

Hi there!

My name’s Rowan and I’m incredibly passionate about plants and greenery and all that good stuff. I’m attempting to get into a career within horticulture but I’m having a bit of trouble.

I didn’t go to university for Horticulture. In fact I think I got a D in GCSE Biology. When I started this journey, the only experience that I had was from owning and taking care of my houseplants, visiting botanical gardens with my family, and that my family garden was beautifully maintained by my Mum.

Since then, I have gotten experience. I moved into a house with my boyfriend and for the first time in a good couple of years, I had the space and permanency to experiment with growing things. We have a greenhouse! Over a couple of years, we’ve been able to grow vegetables from saplings, grow sunflowers to decorate our dinner table, and plant permanent structures which will come back season after season. I’ve was also able to work in a Garden Centre for a time, which boosted my enthusiasm, and I met some really great people.

I’m also pursuing further education so that I can learn more and gain qualifications. I’m currently taking part in the RHS Level 2 Certificate in the Principles of Plant Growth and Development. I’m having so much fucking fun! It’s so interesting and I’m learning how to answer my own questions about horticulture, and I’m surrounded by people who are equally as enthusiastic. This course could really change things for me! I also know that I want to maybe do an apprenticeship in a relevant course, if possible.

And then there’s the problem that I didn’t consider might be a problem when I started. Sure, when I began on this journey, my main goals were “Plants and Greenery” and “Makes me happy”, so I didn’t have the best knowledge of this career sector at the time. I didn’t know what I was missing.

I don’t have a driving license. Most people by the time they’re in their early 20s do, but I don’t. When I was a teenager, the time that people in my country typically learn, the people around my told me that it would be pointless learning because by the time I had somewhere to drive to (i.e. a job), it would be years later, and I would have forgotten. I did buy a motorbike at the age of 19 but that was because I was a teenage rebel, not because of any sense of a need for freedom (I think).  

The COVID-19 Pandemic was what many people considered ‘a shitshow’. Facets of society had to be shut down for long periods of time. By the time things started opening up again, the waitlists for certain things were incredibly long, including the wait for Driving Tests in the UK. For my first test, the wait was 5 months. My second test, which I’m preparing for now, is 6 months.

I probably should have known that a car and a drivers license would be very much needed but eh, hindsight’s 20/20. You might need a car or a driving license because sometimes the work that you’re doing might require you to move location or to transport resources and tools. You might need a car because opportunities in your town come up infrequently and the commute to an exciting job can take 4 hours a day via public transport.

I cannot tell you how many times within the past week that a potential employer has called me up saying “You’ve got a great CV, but we really need you to have a driver’s license.”,

Every 5 or 6 months, I get one shot to gain the qualification which will astronomically better my career. It makes me so angry.

This blog will be used to document my experiments and learning journey so that I can evidence my experience and knowledge to potential employers, and also because it might be a fun place to put my work.

Well, thanks for reading. Here's a photo of the pumpkins I harvested yesterday. See you next time!

[thxnews]

UK Launches New Vaccine Development Center

  Pioneering the Future of Vaccines

In a groundbreaking move, the UK Health Security Agency (UKHSA) has introduced its cutting-edge Vaccine Development and Evaluation Centre (VDEC) today. This innovative facility is poised to build upon the lessons learned from the pandemic and take monumental strides in the creation of life-saving vaccines, both for the United Kingdom and the global community.   A Nexus of Expertise at Porton Down Located at the UKHSA's Porton Down site, VDEC stands as a beacon of scientific collaboration. Operating alongside the Defense Science and Technology Laboratory and other partners, the center has taken residence in an expansive 2,800 square meters of laboratory space. This initiative is an integral part of the UKHSA's comprehensive 3-year strategy, bringing together over 200 esteemed scientists who are devoted to approximately 100 diverse projects. These projects encompass an array of research, including combatting potential pandemic threats posed by deadly pathogens.  

Forging the Path Ahead in Vaccine Development

The core mission of VDEC revolves around its pivotal role in supporting the development of novel vaccines. Through rigorous testing and evaluation, the center examines these vaccines in the context of potential health emergencies. VDEC's endeavors span the entire lifecycle of vaccine development – from the earliest stages of design to the ongoing assessment of vaccine efficacy, especially in the face of emerging variants.   Targeting the Unseen Threats VDEC is committed to addressing challenges posed by pathogens for which vaccines either do not exist or lack adequate regulation in the UK. Diseases like avian influenza, mpox (commonly known as monkeypox), and hantavirus, a severe ailment that transmits from rodents to humans, are among the primary concerns. These endeavors reflect the center's comprehensive approach to safeguarding public health.  

Making Strides in Real-World Solutions

One noteworthy example of VDEC's prowess lies in its ongoing phase one clinical trial. The trials are dedicated to a potential groundbreaking vaccine against Crimean-Congo haemorrhagic fever, a virus that spreads through tick bites and tragically claims about 30% of those infected. Furthermore, VDEC's research extends to combating widespread infections such as tuberculosis and Clostridium difficile, a bacterial infection that poses significant challenges in healthcare settings.  

A Legacy of Preparedness

VDEC's establishment is a testament to the UK's dedication to preparedness. As an extension of capabilities honed during the COVID-19 crisis, the center's focus transcends pandemics and embraces a wider array of lethal pathogens and diseases. Bolstered by a unique set of capabilities geared towards high-consequence infectious diseases, VDEC is a global leader in research, its results resonating with trust, quality, and safety.   A Vision for Progress Professor Dame Jenny Harries, the Chief Executive of UKHSA, heralds VDEC as an exhilarating leap forward in the realm of vaccine research. With an unwavering commitment to combating infectious disease threats, the center is poised to spearhead critical research that contributes to the UK's status as a scientific powerhouse.   Pioneering Global Health Solutions Beyond its connection to the aftermath of COVID-19, VDEC's scope encompasses an extensive range of deadly viruses and pathogens. This dedication to global health and welfare stands as a hallmark of the center's mission.  

Driving the 100 Days Mission

Integral to the global 100 Days Mission launched under the UK G7 presidency, VDEC's role is indispensable in achieving its visionary goals. This mission strives to develop diagnostics, therapeutics, and vaccines within a swift 100 days of identifying a new pandemic threat. Today's report by UKHSA underscores significant advancements in vital areas like vaccine research, development, and manufacturing.   The Torchbearers of Preparedness Professor Isabel Oliver, the Chief Scientific Officer of UKHSA, emphasizes VDEC's crucial role in the 100 Days Mission. This mission, aiming to forestall the impact of potential pandemics, showcases the UK's leadership in identifying and combating evolving health threats. The global, national, and local impact of UKHSA's scientific endeavors remains resolute.   Shaping a Resilient Future Steve Barclay, Secretary of State for Health and Social Care, lauds VDEC as a monumental milestone. This state-of-the-art facility bolsters the UK's stature in pandemic preparedness, vaccine development, and scientific exploration. The contributions of VDEC's esteemed scientists stand to safeguard lives across the globe.  

Exemplary VDEC Initiatives

VDEC's portfolio boasts a range of groundbreaking initiatives, each designed to advance our understanding of infectious diseases and their potential remedies.   Unveiling the Effectiveness of Vaccines Amid the COVID-19 outbreak, VDEC's scientists innovated a one-of-a-kind assay to gauge the potency of emerging vaccines. By analyzing blood samples from both infected individuals and those who were vaccinated, they assessed the ability to neutralize the live SARS-CoV-2 virus. This method, initially capable of testing around 100 samples weekly, has evolved into a high-throughput process evaluating approximately 3,000 samples weekly, spanning various diseases.   Confronting the Crimean-Congo Threat VDEC's scientific prowess unveiled the potential for a vaccine against Crimean-Congo haemorrhagic fever, an affliction with a daunting 30% fatality rate. As the vaccine progresses through stage one clinical trials, it holds promise as a global breakthrough.   Tackling Seasonal Influenza Head-On VDEC has magnified its capacity to expedite the evaluation of influenza vaccines from around the world. This acceleration enables quicker responses in proving vaccine effectiveness during major outbreaks.   Avian Influenza: A Unique Challenge VDEC stands as a rare facility capable of handling a high-containment pathogen like avian influenza. Scientists are actively setting the groundwork to assess vaccines from private developers against this formidable pathogen.   Anticipating 'Disease X' Leveraging immunological assays, VDEC researchers gauge vaccine effectiveness against bacterial infections. These assays could play a pivotal role in combating emerging pathogens with pandemic potential.   Streamlined Drug Screening VDEC's enhanced capabilities empower scientists to simultaneously test hundreds, even thousands, of therapeutic drugs against novel pathogens. This high-throughput approach expedites the identification of effective treatments. In the grand tapestry of scientific progress, VDEC's inauguration serves as a milestone in humanity's collective efforts to safeguard against devastating health threats. Armed with visionary experts, cutting-edge technology, and a commitment to global welfare, this world-leading center epitomizes the resilience and ingenuity that shape a healthier future for all. Sources: THX News & UK Health Security Agency.   Read the full article

[ffcarlos-grad604]

More Designs by Aotearoa Creatives (part 1)

Alexander Muruo – Good Health

Project Description

Research suggests feeling ‘average’ has become the new norm for a huge proportion of the country. The pace of modern life contributes to all sorts of health issues, amplified by the ongoing effects of COVID-19. Working with agency Hello we created a campaign for "GoodHealth" that holds up a mirror to our daily lives and demonstrates the stresses many of us are under. This is a montage of moments from the campaign.

Biography

Alexander Muruo’s work experience includes being a Lead Designer at Disney in Moscow, Russian Federation, Motion Graphics Designer, and Art Director / Motion Designer in BUNKER — Auckland, New Zealand.

Becca Aiken – Wedding Stationery

Project Description

Kristin and Lucy sought a wedding stationery suite that captured their unique story in a non-traditional way. As a couple who value experiences and moments, I identified the theme of international living and travel, brought to life through memories made along the way.

The suite was executed through formats that connected to their lives. With passions and professions in print and design, the visual language and illustrations communicated key milestones in their relationship. Enhancing a minimalist yet detailed approach, technical print production played an essential role in the suite.

Biography

Becca Aiken is a New Zealand illustrator, designer, and brand developer living and creating in Christchurch, NZ. She is inspired by my surroundings and has worked with a range of different clients from personal commissions to larger corporate bespoke pieces. Aiken currently works as a Senior Brand Manager at Giesen Group Limited.

Ben Galbraith – Neptunes Pizzeria

Project Description

Founded in 2020 Neptunes pizzeria is a family run business based in Gisborne, New Zealand. Leah and her team source the best local produce and hand make everything from scratch - this provided a great opportunity to create a bold, crafted and memorable icon, which stands out from the fast food franchises further up the street. Positioned within casting distance from the Fishing Port, the brand takes on a nautical theme with a colour palette inspired by the east coast. The identity centres around a hand drawn Neptune icon rising from the waters of the East Coast with a slice of pizza speared onto his trident. By going against the current Neptunes Pizzeria has developed a cult following of their legendary pizza!

Biography

Ben Galbraith is a designer with over 15 years’ experience. He’s worked for some of the top design studios in the UK, Australia and Singapore. His strength is in storytelling, adding personality, humour, and creating brands that stand out. He loves building new brands from the ground up or helping established brands win new markets and increase sales.

Chris Flack - Optimal Workshop Empathy Engine

Project Description

Optimal Workshop provides usability testing tools and research methods to help researchers, designers and information architects improve the user experience of their products.

A 38-page, A4, printed booklet that helps inspire and engage readers whilst familiarising their quirky, fun brand culture and business ethos.

Biography

Chris Flack was born and raised in Dunedin. During his first year at Otago University he saw a flyer for a graphic design course at the Design & Arts College in Christchurch. This course also offered a scholarship, so he applied and got it. He is currently a design director at Strategy, an independent, strategy, branding and product company, with offices in Auckland, Wellington and Dunedin.

Catherine Marion – European Finches

Biography

Catherine Marion is an artist most known for her intricate botanical patterns & colourful illustrations. Her work aims to reconnect people to nature through colourful & stylistic designs.

Project Description

First started this illustration with a hand drawn sketch then added colours and details to the artwork in Adobe Fresco before creating the final texture in Photoshop.

[theborderupdates]

Moving to the UK: An Ultimate Guide for Nigerian Students

Are you a Nigerian student looking to study in the UK? The number of Nigerians wishing to study in the UK has been steadily increasing since 2018, with a 47% year-on-year increase from 1,620 in 2021 to 2,380 in 2022. In January, UK Visas & Immigration (UKVI) resumed study visa processing for Nigerian students after temporarily suspending it due to the impact of COVID-19 on courier routes.

However, UKVI is currently prioritising Ukraine Family Scheme applications in response to the Russia-Ukraine war, which may cause delays for other visa applications. Despite this, with proper time management and planning, you can get your student visa application approved and begin your studies in the UK.

Here are some things you need to know;

Nigerian Students: Securing Admissions, a Student Visa

Before applying for a programme at your dream university, make sure you meet the necessary qualifications for the programme. Once you have received a conditional offer, you will need to provide supporting documents including a transcript of your academic qualifications, a CV or resume (for postgraduate study), a copy of your passport, a reference or recommendation letter, a personal statement, and an English language qualification such as IELTS, SSEC, WAEC with a grade of C6 or above, or TOEFL.

Obtain Your CAS Number

After finalizing everything, you will receive an unconditional offer from your university, and you will be asked to make a deposit, which can vary depending on your program and institution. For example, at the University of Sussex, self-funded international students who are starting a master's program may need to pay a tuition fee deposit of 2,000 pounds.

According to the University of Westminster, all international applicants must pay a minimum deposit of £4000 before receiving a Confirmation of Acceptance for Studies (CAS).

The following step is to make sure that your university issues you a CAS number. A CAS number is evidence that you have received an unconditional offer from your university and is required for your student visa application. If your university does not provide you with your CAS number, contact them directly.

Complete a Tuberculosis (TB) Test

If you're planning to study in the UK for more than six months, taking a TB test is mandatory, and you'll need to submit the results to UKVI during your visa application. The only recognised centre by UKVI for TB screening is the Migration Health Assessment Centre at the International Organisation for Migration (IOM). The cost of the test is approximately 57,800 nairas, and you'll receive your results on the same day.

Begin Your UK Student Visa Application

The following is a list of everything you will need for your student visa application:

A bank statement

Proof of funds (to demonstrate that you have the financial capability to cover your tuition fees and living expenses)

A sponsorship letter (written by your parent or guardian who will be sponsoring you)

A birth certificate or equivalent (to verify your relationship with your sponsor)

A CAS letter from your university

TB test results

An offer letter from your university

All of the documents you previously submitted for your university admission, including a copy of your passport, transcripts, and so on.

After gathering all the required documents, you will need to apply for your student visa online. Don't worry if you can't complete the application form in one sitting, as you can save your progress and return to it later.

Upon submitting your documents, you will be directed to a TLS webpage where you will need to make two payments: a health surcharge of approximately US$900 and a visa application fee of around US$478.

Once you have made your payments, you will need to schedule an appointment on the same website to visit one of the three UK Visa Application Centres in Nigeria: Abuja, Lagos Ikeja, or Lagos Victoria Island (additional fees apply at this location). At the centre, you will need to provide your biometric information (fingerprint and photograph).

It is worth noting that getting an appointment can be challenging, and you can opt for a walk-in visa application, which incurs an additional fee of approximately 42,000 Naira.

After submitting your biometric information, it will take approximately 15 working days to process a standard student visa and five working days for a PV student visa. Finally, it is essential to keep checking relevant government websites for the latest travel updates. Best of luck!

[prudentiacare]

Newcastle Home Care

Home care (also called domiciliary care) is tailored support delivered flexibly in your own home. It is a great solution for the elderly, people with disabilities or long-term illness.

There are a range of Home Care agencies in Newcastle Upon Tyne who provide a variety of services, including:

Home Care Assistance

Home care assistance is a way to provide elderly adults with extra help in their homes. It can reduce caregiver stress, curb senior loneliness, and make daily life easier for your loved one.

Newcastle home care offers a variety of services for seniors, including weekly companionship and personal care. It also offers specialized in-home care for those recovering from strokes or living with cancer or Parkinson’s disease.

The agency follows COVID-19 safety procedures to keep both clients and caregivers safe and healthy. It has a network of qualified caregivers who are experienced CNAs, LPNs, and LVNs.

If you are aged 65 or over (50 years or older for Aboriginal and Torres Strait Islanders) you can apply for a government funded Home Care Package. These packages are tailored to your needs and include transport, help with meals, housework, and more.

Home Care Services

The Newcastle home care team offers a range of services, from companionship and housekeeping, through to complex clinical support and palliative care. These can be provided on an hourly visiting basis or as full-time live-in care.

Our team has over 20 years of experience in Newcastle and will match you with the perfect live-in carer, based on your needs. You can ring, email or start a live chat to discuss your requirements and get connected to a Care Adviser who will be delighted to help.

You may be able to get help with home care fees from your local council. This is usually via a means test, which looks at your income and assets to see if you can afford the cost of the care.

Your local council can also give you up to four weeks of free personal care if you are aged over 65. This can include assistance with getting out of bed, bathing and eating.

Home Care Providers

Home care providers in Newcastle come in all shapes and sizes, from domiciliary agencies that visit clients to large, multi-national organizations. Some of them offer services like nursing or allied health input, memory and behaviour support and aids and appliances. For the most part, you can expect to pay on an hourly basis. But some home care companies offer bundled options for patients that qualify. This is particularly true for Medicare (or a Medicare Advantage plan with whom they are in-network) and Medicaid beneficiaries. The best part is, the majority of these companies are regulated by the Care Quality Commission and can be found with a little legwork.

To find the best home care provider for your loved one, we recommend using Care Sourcer’s patented matching technology to match you with the top-rated home care providers in your area. It’s as easy as entering your postcode and clicking submit. Or, if you prefer to speak to someone, our team of UK based care experts are available to answer your questions and make suggestions on how to find the best home care for you or your loved one.

Home Care in Newcastle

Home care (domiciliary care) is tailored support delivered in the comfort of your own home, ideal for the elderly or those living with a disability. A home care agency can provide you with a personal carer who will help with a range of tasks such as dressing, bathing, cooking and medication assistance.

My mum has been receiving home care for the past four years, she was so relieved to have the peace of mind that a professional carer was looking after her needs. The carers are very polite, helpful and friendly. They are also able to make trips out, take my mum shopping and to garden centres.

There are 51 home care agencies regulated by the Care Quality Commission in Newcastle upon Tyne. To find a reputable agency, you can use the InformationNOW directory or speak to Community Health and Social Care Direct for more information. They can arrange a needs assessment and give you advice.